Kilitch Drugs Valuation
| KILITCH Stock | 354.65 7.70 2.13% |
At this time, the firm appears to be overvalued. Kilitch Drugs Limited secures a last-minute Real Value of USD283.72 per share. The latest price of the firm is USD354.65. Our model forecasts the value of Kilitch Drugs Limited from analyzing the firm fundamentals such as Profit Margin of 0.11 %, current valuation of 5.38 B, and Return On Equity of 0.0832 as well as examining its technical indicators and probability of bankruptcy.
Price Book 3.0781 | Enterprise Value 5.4 B | Enterprise Value Ebitda 16.0492 | Price Sales 3.0567 | Trailing PE 28.5037 |
Overvalued
Today
Please note that Kilitch Drugs' price fluctuation is very steady at this time. Calculation of the real value of Kilitch Drugs Limited is based on 3 months time horizon. Increasing Kilitch Drugs' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Kilitch Drugs is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Kilitch Stock. However, Kilitch Drugs' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 354.65 | Real 283.72 | Hype 355.74 | Naive 385.61 |
The intrinsic value of Kilitch Drugs' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Kilitch Drugs' stock price.
Estimating the potential upside or downside of Kilitch Drugs Limited helps investors to forecast how Kilitch stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Kilitch Drugs more accurately as focusing exclusively on Kilitch Drugs' fundamentals will not take into account other important factors: Kilitch Drugs Cash |
|
Kilitch Drugs Total Value Analysis
Kilitch Drugs Limited is now anticipated to have takeover price of 5.38 B with market capitalization of 5.56 B, debt of 316.46 M, and cash on hands of 1.34 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Kilitch Drugs fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.38 B | 5.56 B | 316.46 M | 1.34 M |
Kilitch Drugs Investor Information
About 75.0% of the company outstanding shares are owned by corporate insiders. The book value of Kilitch Drugs was now reported as 117.76. The company recorded earning per share (EPS) of 12.13. Kilitch Drugs Limited last dividend was issued on the 20th of September 2019. Based on the key indicators related to Kilitch Drugs' liquidity, profitability, solvency, and operating efficiency, Kilitch Drugs Limited is performing exceptionally good at this time. It has a great probability to report excellent financial results in April.Kilitch Drugs Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Kilitch Drugs has an asset utilization ratio of 64.31 percent. This signifies that the Company is making USD0.64 for each dollar of assets. An increasing asset utilization means that Kilitch Drugs Limited is more efficient with each dollar of assets it utilizes for everyday operations.Kilitch Drugs Ownership Allocation
Kilitch Drugs Limited maintains a total of 16.08 Million outstanding shares. Kilitch Drugs Limited secures majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 75.15 % of Kilitch Drugs Limited outstanding shares that are owned by insiders conveys that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Kilitch Drugs Profitability Analysis
The company reported the revenue of 1.54 B. Net Income was 193.54 M with profit before overhead, payroll, taxes, and interest of 808.42 M.About Kilitch Drugs Valuation
An absolute valuation paradigm, as applied to Kilitch Stock, attempts to find the value of Kilitch Drugs Limited based on its fundamental and basic technical indicators. By analyzing Kilitch Drugs's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Kilitch Drugs's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Kilitch Drugs. We calculate exposure to Kilitch Drugs's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Kilitch Drugs's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 713.5 M | 749.2 M |
Kilitch Drugs Quarterly Retained Earnings |
|
Complementary Tools for Kilitch Stock analysis
When running Kilitch Drugs' price analysis, check to measure Kilitch Drugs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kilitch Drugs is operating at the current time. Most of Kilitch Drugs' value examination focuses on studying past and present price action to predict the probability of Kilitch Drugs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kilitch Drugs' price. Additionally, you may evaluate how the addition of Kilitch Drugs to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |